Inhibitory activity of 9-phenylcyclohepta[d]pyrimidinedione derivatives against different strains of HIV-1 as non-nucleoside reverse transcriptase inhibitors
2011

New HIV-1 Inhibitor Shows Promise

publication Evidence: moderate

Author Information

Author(s): Huang Yang, Wang Xiaowei, Yu Xiaoling, Yuan Lin, Guo Ying, Xu Weisi, Liu Tiejun, Liu Junyi, Shao Yiming, Ma Liying

Primary Institution: State Key Laboratory for Infection Disease Prevention and Control, National Center for AIDS/STD Control and Prevention (NCAIDS), Chinese Center for Disease Control and Prevention (CDC), China

Hypothesis

Can 9-phenylcyclohepta[d]pyrimidinedione derivatives effectively inhibit HIV-1?

Conclusion

BmPCP is effective against a broad spectrum of HIV-1 strains and can serve as a lead compound for new anti-HIV-1 drugs.

Supporting Evidence

  • BmPCP showed IC50 values of 0.34 μM and 1.96 μM against different HIV-1 strains.
  • The selectivity index of BmPCP ranged from 67 to 266 in various cell types.
  • BmPCP effectively inhibited HIV-1 infection in laboratory-adapted strains and clinical isolates.

Takeaway

A new compound called BmPCP can help fight HIV by stopping the virus from making copies of itself.

Methodology

The study involved testing the antiviral activity of BmPCP against various HIV-1 strains in different cell types.

Limitations

BmPCP was less effective against NNRTI drug-resistant strains.

Digital Object Identifier (DOI)

10.1186/1743-422X-8-230

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication